Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.38
-0.0400-2.82%
Post-market: 1.380.00000.00%16:04 EDT
Volume:42.32K
Turnover:58.91K
Market Cap:67.82M
PE:-5.64
High:1.42
Open:1.41
Low:1.37
Close:1.42
52wk High:1.96
52wk Low:1.13
Shares:49.15M
Float Shares:42.08M
Volume Ratio:0.37
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2449
EPS(LYR):-0.2445
ROE:-25.50%
ROA:-16.36%
PB:1.63
PE(LYR):-5.64

Loading ...

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

GlobeNewswire
·
Dec 18, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 09, 2025

Medicinova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) Presented at the 36TH International Symposium on ALS/Mnd

THOMSON REUTERS
·
Dec 08, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire
·
Dec 08, 2025

MediciNova Inc - May Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

MediciNova Reveals MN-001 Metabolite Boosts Cholesterol Efflux in Macrophages

Reuters
·
Dec 02, 2025

Message from the CEO to MediciNova Shareholders

GlobeNewswire
·
Dec 02, 2025

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

TIPRANKS
·
Nov 18, 2025

Press Release: MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Dow Jones
·
Nov 18, 2025

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire
·
Nov 07, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 04, 2025

BRIEF-MediciNova Completes Patient Enrollment In MN-001 Trial For Tipelukast In MN-001-NATG-202 Study

Reuters
·
Nov 04, 2025

MediciNova Completes Enrollment in Phase 2 Trial of Tipelukast for NAFLD and Hypertriglyceridemia

Reuters
·
Nov 04, 2025

Medicinova Announces Completion of Patient Enrollment in Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
Nov 04, 2025

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire
·
Nov 04, 2025

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 31, 2025

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

Benzinga_recent_news
·
Oct 31, 2025

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

TIPRANKS
·
Oct 31, 2025

MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study

Reuters
·
Oct 31, 2025

MediciNova Inc. to Present Corporate Overview at LD Micro Main Event XIX Investor Conference

Reuters
·
Oct 06, 2025